JNJ logo

Johnson & Johnson Stock Price

NYSE:JNJ Community·US$555.9b Market Cap
  • 4 Narratives written by author
  • 2 Comments on narratives written by author
  • 912 Fair Values set on narratives written by author

JNJ Share Price Performance

US$0
-151.87 (-100.00%)
US$173.55
Fair Value
US$0
-151.87 (-100.00%)
Price US$0

JNJ Community Narratives

Goran_Damchevski·
Fair Value US$173.55 34.3% overvalued intrinsic discount

Rich Drug Pipeline Will Push Revenues and Earnings Higher

17users have liked this narrative
1users have commented on this narrative
46users have followed this narrative
AnalystConsensusTarget·
Fair Value US$224.09 4.0% overvalued intrinsic discount

Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments

6users have liked this narrative
0users have commented on this narrative
443users have followed this narrative
AnalystHighTarget·
Fair Value US$265 12.0% undervalued intrinsic discount

Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory

2users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
US$265
12.0% undervalued intrinsic discount
Revenue
7.1% p.a.
Profit Margin
22.64%
Future PE
29.88x
Price in 2029
US$323.61

Trending Discussion

Updated Narratives

JNJ logo

Rich Drug Pipeline Will Push Revenues and Earnings Higher

Fair Value: US$173.55 34.3% overvalued intrinsic discount
46 users have followed this narrative
1 users have commented on this narrative
1 users have liked this narrative
JNJ logo

Industry Tailwinds, Company Headwinds And New Products Will Lead To Stable Revenue Growth

Fair Value: US$133 75.3% overvalued intrinsic discount
14 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JNJ logo

JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward

Fair Value: US$224.09 4.0% overvalued intrinsic discount
443 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record established dividend payer.

2 Risks
3 Rewards

Johnson & Johnson Key Details

US$94.2b

Revenue

US$30.1b

Cost of Revenue

US$64.1b

Gross Profit

US$37.3b

Other Expenses

US$26.8b

Earnings

Last Reported Earnings
Dec 28, 2025
Next Reporting Earnings
Apr 14, 2026
11.13
68.07%
28.46%
57.8%
View Full Analysis

About JNJ

Founded
1886
Employees
138100
CEO
Joaquin Duato
WebsiteView website
www.jnj.com

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Recent JNJ News & Updates

Recent updates

No updates